Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Oxurion NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Oxurion NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Oxurion NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Oxurion NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Oxurion NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Oxurion NV, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Oxurion Enters into Research Agreement with Beta Therapeutics 11
ThromboGenics Forms Joint Venture with VIB 12
Licensing Agreements 13
Oncurious Enters into Licensing Agreement with VIB 13
ThromboGenics Enters into Licensing Agreement with Galapagos 14
ThromboGenics Expands Licensing Agreement with Bicycle Therapeutics 15
ThromboGenics Enters into Licensing Agreement with Grifols 16
Equity Offering 17
ThromboGenics Plans to Raise USD11.8 Million in Private Placement of Shares 17
ThromboGenics Completes Private Placement Of Shares For US$103.7 Million 18
Oxurion NV – Key Competitors 20
Oxurion NV – Key Employees 21
Oxurion NV – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Financial Announcements 23
Sep 06, 2018: ThromboGenics business update – H1 2018 23
May 09, 2018: ThromboGenics Business Update – Q1 2018 25
Mar 15, 2018: ThromboGenics Business Update – FY 2017 27
Sep 07, 2017: ThromboGenics Business Update – H1 2017 32
Mar 16, 2017: ThromboGenics Business Update – FY 2016 36
Corporate Communications 40
Oct 29, 2018: Oxurion names Adrienne Graves as board director 40
Nov 08, 2017: ThromboGenics Strengthens Leadership Team 41
Jun 15, 2017: Thomas Clay Appointed Chairman of the Board of Directors 42
Product News 43
04/20/2017: Thrombogenics Achieves Important Milestone In The Development Of THR-149, A Novel Plasma Kallikrein Inhibitor For Diabetic Macular Edema 43
04/04/2018: ThromboGenics Reports Initial Data from its Clinical Study evaluating THR-317 44
Product Approvals 45
Jan 17, 2017: ONCURIOUS Announces European Commission Confirmed Orphan Medicinal Product Designation for TB-403 for Medulloblastoma 45
Clinical Trials 46
Apr 27, 2018: ThromboGenics Initiates Phase 2 Clinical Study Evaluating anti-PlGF (THR-317) in combo with anti-VEGF (ranibizumab) for treatment of DME 46
Apr 06, 2018: ThromboGenics announces publication in The Journal of Medicinal Chemistry of preclinical data supporting therapeutic potential of THR-149, a plasma kallikrein inhibitor, in Diabetic Macula Edema 47
Oct 09, 2017: ThromboGenics announces publication in Experimental Eye Research of preclinical data supporting therapeutic potential of THR-317 in DR 48
Sep 27, 2017: ThromboGenics: ThromboGenics Presenting THR-687 Preclinical Data at European Association for Vision and Eye Research (EVER) Meeting 49
May 24, 2017: ThromboGenics to present THR-317 Pre-clinical Research Findings at the European Association for the Study of Diabetes, Eye Complications Study Group Meeting in Budapest, Hungary 50
Jan 10, 2017: ThromboGenics Enrolls First Patients in Phase II Clinical Study Evaluating THR-317 (Anti-PlGF) for Diabetic Macular Edema 51
Other Significant Developments 52
Sep 03, 2018: ThromboGenics becomes “Oxurion” 52
Jun 27, 2018: ThromboGenics Plans Name Change to “Oxurion” 53
Jun 21, 2018: ThromboGenics Partners with Prevent Blindness at 2018 Focus on Eye Health National Summit in Washington DC 54
Oct 20, 2017: ThromboGenics Business Update – Q3 2017 55
May 11, 2017: ThromboGenics Business Update – Q1 2017 58
Appendix 60
Methodology 60
About GlobalData 60
Contact Us 60
Disclaimer 60
Oxurion NV, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Oxurion NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Oxurion NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Oxurion NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Oxurion NV, Deals By Therapy Area, 2012 to YTD 2018 9
Oxurion NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Oxurion Enters into Research Agreement with Beta Therapeutics 11
ThromboGenics Forms Joint Venture with VIB 12
Oncurious Enters into Licensing Agreement with VIB 13
ThromboGenics Enters into Licensing Agreement with Galapagos 14
ThromboGenics Expands Licensing Agreement with Bicycle Therapeutics 15
ThromboGenics Enters into Licensing Agreement with Grifols 16
ThromboGenics Plans to Raise USD11.8 Million in Private Placement of Shares 17
ThromboGenics Completes Private Placement Of Shares For US$103.7 Million 18
Oxurion NV, Key Competitors 20
Oxurion NV, Key Employees 21
Oxurion NV, Other Locations 22
Oxurion NV, Subsidiaries 22
List of Figures
Oxurion NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Oxurion NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Oxurion NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Oxurion NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Oxurion NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Oxurion NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Oxurion NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Oxurion NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9